VYNE Therapeutics Inc.
About VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $570.0K
- Net income
- -$26.5M
- Total assets
- $30.2M
- Market cap
- $21.9M
- Operating margin
- -5219.1%
- Net margin
- -4646.1%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $570.0K
- Operating expenses
- $30.3M
- Operating income
- -$29.7M
- Income tax
- $4.0K
- Net income
- -$26.5M
- EPS (basic)
- $-0.62
- EPS (diluted)
- $-0.62
Balance sheet
- Total assets
- $30.2M
- Current assets
- $30.0M
- Total liabilities
- $2.4M
- Current liabilities
- $2.4M
- Shareholders’ equity
- $27.8M
Cash flow
- Operating cash flow
- -$33.1M
- Investing cash flow
- $37.4M
- Financing cash flow
- -$143.0K
- Net cash flow
- $4.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $21.9M
- EPS (diluted)
- $-0.62
- Shares outstanding
- 33.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 25, 2018
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $26.5M in FY2025.
- Revenue declined 96% from FY2021 to FY2025.
- Trading 63% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review VYNE Therapeutics Inc..
Write a review
News about VYNE Therapeutics Inc.
News & sentiment via Polygon.io
